home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2823.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
40 lines
Document 2823
DOCN M94A2823
TI Anti-CMV human immunoglobulins in the prophylaxis of HCMV disease in HIV
positive patients. Preliminary results.
DT 9412
AU Traina C; Magaraci G; Bellissima P; Panella L; Di Stefano G; Zola S;
Centro AIDS USL 58, Palermo, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):217 (abstract no. PB0296). Unique
Identifier : AIDSLINE ICA10/94369752
AB OBJECTIVE: To prevent or delay the spread of the HCMV disease in HIV
positive patients, by using human anti-CMV immunoglobulins. METHODS:
Between November 1992 and October 1993, in a 2 phases multicentric
clinical trial, were enrolled 48 patients (average age 29 years),
including HIV positive patients with CD4+ < 300/mmc belonging to the
following groups: I: anti-HCMV IgM and IgG negative--II: anti-HCMV IgM
negative, anti-HCMV IgG positive--III: patients with previous HCMV
disease. The therapy requires the intramuscular administration of 0.25
ml/Kg human anti CMV immunoglobulins every 28 days for 24 months.
RESULTS: The average follow up time was 6 months (range 1-10 months). At
enrollment the average number of CD4+ cells was 185/mmc, after a three
months follow up it rose to 198/mmc and after 6 months to 204/mmc,
whilst the CD4+/CD8+ ratio had changed after 6 months going from 0.29 to
0.35, moreover we noted an increase in the CD16-CD25 and Dr lymphocytic
subsets, the absence of HCMV in the blood and urines and none
reinfections from HCMV in the patients undergone to human anti CMV Ig
prophylaxis. CONCLUSIONS: These encouraging data impel us to continue
our study on a larger number of patients in random clinical trials with
the aim of preventing or delaying the clinical manifestations of this
opportunistic agent.
DE Adult Antibodies, Viral/BLOOD/*THERAPEUTIC USE AIDS-Related
Opportunistic Infections/MICROBIOLOGY/*PREVENTION & CONTROL
Comparative Study Cytomegalovirus/*IMMUNOLOGY Cytomegalovirus
Infections/*PREVENTION & CONTROL CD4-CD8 Ratio Human IgG/BLOOD
IgM/BLOOD *Immunization, Passive Leukocyte Count Treatment Outcome
T4 Lymphocytes CLINICAL TRIAL MEETING ABSTRACT MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).